| Feature . | Pancreatic . | Extrapancreatic (duodenal) . |
|---|---|---|
Number of patients | 81 | 81 |
Inhibitory syndrome (%) | 18.5 | 2.5 |
von Recklinghausen’s disease (%) | 1.2 | 43.2 |
Large tumour (>20 mm) (%) (NFI) | 85.5 | 41.4 |
Multisecretorary activity (%) | 33.3 | 16.3 |
Metastatic rate and malignancy | No differences | |
5-year survival | 75.2% overall 59.9% with metastases 100% without metastases |
| Feature . | Pancreatic . | Extrapancreatic (duodenal) . |
|---|---|---|
Number of patients | 81 | 81 |
Inhibitory syndrome (%) | 18.5 | 2.5 |
von Recklinghausen’s disease (%) | 1.2 | 43.2 |
Large tumour (>20 mm) (%) (NFI) | 85.5 | 41.4 |
Multisecretorary activity (%) | 33.3 | 16.3 |
Metastatic rate and malignancy | No differences | |
5-year survival | 75.2% overall 59.9% with metastases 100% without metastases |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
